Breviscapine, is the total flavonoid constituents (the content of scutellarin у85%) extracted from the dried whole plant of Erigeron breviscapus (VANT.) HAND.-MAZZ, 1) which has been used as a folk medicine to cure paralysis for a long period in Yunnan province of China. Modern pharmacological study indicated that breviscapine could improve cerebral microcirculation and increase cerebral blood flow; inhibit the platelet activation and aggregation, and prevent thrombosis formation, etc.
The latest research indicates that breviscapine is in favor of myocardial protection 4) and shows promising effect on renal protection. 5) Due to the distinguished efficacy of breviscapine in the clinical therapy, the research of breviscapine has become a hot topic in China in recent years.
Pharmacokinetic studies on breviscapine or scutellarin have been much investigated in rats, 6 ) rabbits 7) and dogs 8) after oral administration, and Ge Q. H. et al. have revealed that the oral absolute bioavailability was quite poor in dogs. 8) Up to now, data available on metabolism of breviscapine or scutellarin in rats was limited to the literature published previously, 9) the results of which showed that scutellarin was metabolized in rats to a large extent and mainly excreted in urine and bile as metabolites, however, some of the metabolites were not identified since only HPLC-NMR and HPLC-MS were used as the analytical methods to deduce the structures of the metabolites.
To gain deep insight into its metabolic fate, we examined the biotransformation of breviscapine after oral administration to rats. The present study describes the isolation and identification of ten metabolites of breviscapine. Isolation of the Flavonoid Constituents of Breviscapine One major and three minor flavonoid components were observed in breviscapine by HPLC analysis (Fig. 1) . After being auto-integrated by the Millennium 32 workstation, it was displayed that the relative content of the major flavonoid component was about 89%. The chromatographic separation was performed on a C 18 column (Inertsil ODS-2, 5 mm, 4.6ϫ 250 mm) at a column temperature of 25°C, and mobile phase was MeOH-H 2 O (50 : 50), containing 0.1% phosphoric acid. The detection wavelength was set at 335 nm. The composition of the analytical HPLC system see 'Spectroscopic Methods'.
MATERIALS AND METHODS

Materials
The breviscapine sample (400 mg) dissolved in CH 3 OH was subjected to RP-18 silica gel column chromatography with a MeOH-H 2 O solvent (30 : 70, 40 : 60, 50 : 50, 60 : 40), and subsequently, the 40% and 50% MeOH elution were further purified by preparative HPLC performed with an ODS column (Xterra ODS 19ϫ300 mm; Waters Corp.) in a waters 600 liquid chromatograph apparatus equipped with a Waters 490 UV detector (Waters, Milford, MA, U.S.A.). The detection wavelength was 335 nm. Elution was carried out with MeOH-H 2 O containing 0.1% phosphoric acid at a flow rate of 10 ml/min. Elution with MeOH-H 2 O (38 : 62) yielded plantaginin (3 mg) and scutellarin (310 mg). Elution with MeOH-H 2 O (42 : 58) yielded apigenin-7-O-b-D-glucuronide (5 mg) and scutellarein (3 mg). The four compounds were identified by means of spectral methods including [10] [11] [12] [13] Animals Male Wistar rats (200Ϯ20 g body weight) were provided by the Animal Center of Shenyang Pharmaceutical University (Shenyang, China). The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Shenyang Pharmaceutical University. These animals were kept in a breeding room to be acclimated for 7 d before use. Normal food and water were available at all times except that they were withdrawn 12 h prior to experimentation.
Rats Urinary Samples for HPLC-DAD (High Performance Liquid Chromatography-Diode Array Detector) Analysis and Chromatographic Conditions Male Wistar rats were fasted 12 h before they were administered breviscapine orally (50 mg/kg) during which water could be available freely, then using metabolic cages to collect 36 h urine (approximately 20 ml/rat) which was adjusted pH to about 5.0 with phosphoric acid, and rats were free to drink water. The urinary sample was subjected to D101 macroporous absorption resin eluted with water and 70% ethanol, after the 70% eluting fraction was evaporated to dryness at 40°C, the residue was reconstituted with 0.2 ml 50% methanol followed by centrifugation at 3000 rpm for 10 min, and the supernatant of 20 ml was subjected to HPLC system after being filtered through a 0.5 mm membrane. The preparation of blank sample was the same as the process described above except that the rats of control group were not administered drug.
The chromatographic separation was performed on a C 18 reversed-phase column (Inertsil ODS-3, 5 mm, 3.9ϫ150 mm) at a column temperature of 25°C, the mobile phase consisted of solvent A (30% methanol, containing 0.1% phosphoric acid) and solvent B (70% methanol, containing 0.1% phosphoric acid). Conditions: linear gradient (A/Bϭ100/0→0/ 100, 60 min) and then keeping solvent B for 20 min at a flow rate of 1.0 ml/min. The detection wavelength was set at 335 nm. The composition of the analytical HPLC system see 'Spectroscopic Methods'. The result was shown in Fig. 2 .
Rats Urine Collections For the identification of metabolites, sixty male Wistar rats were employed and fasted 12 h prior to experimentation, during which only water was provided. They were administered breviscapine orally at a dose of 50 mg/kg and reiteratively in an interval of 7 d (2 d for administration and 5 d for recovery), and the urine was collected between 0 to 36 h, during which water could be available freely. The pH of the collective urine was adjusted to about 5.0 with phosphoric acid, and placed in the refrigerator at Ϫ10°C subsequently.
Isolation of Metabolites
The cumulative urinary samples (approximately 20000 ml in total) were thawed at room temperature, and successively subjected to macroporous absorption resin D101 eluted with H 2 O/EtOH in a stepwise manner. The 30% and 50% EtOH elution was subjected to RP-18 silica gel column chromatography with a MeOH-H 2 O solvent system varying from water to methanol respectively. The fractions containing the metabolites of both were further purified by preparative HPLC.
Purification by HPLC Preparative HPLC was performed with an ODS column (C 8 extracted with ethyl acetate and after the organic layer was evaporated to dryness in vacuum, the residues were reconstituted in 0.2 ml methanol for HPLC and ESI-MS analysis.
Spectroscopic Methods Electrospray ion trap mass spectrometry in a multistage full scan mode was performed on an Agilent 1100 serials SL instrument (Agilent, U.S.A.) having a mass range of 60 to 2200. The instrument was operated in the negative ion mode, using nitrogen for nebulizing and dry gas. The collision-induced dissociation of [MϪH] Ϫ was achieved with helium as the collision gas. The ionization was performed applying the following parameters: capillary temperature, 300°C; capillary voltage, Ϫ4.0 kV. Sample solutions were directly introduced into the ESI source at a flow rate of 5 ml/min by a springe pump.
NMR spectra were measured on a Bruker AV-600 spectrometer, and chemical shifts are given in ppm downfield relative to tetramethylsilane. All compounds were dissolved in (CD 3 ) 2 SO.
UV absorption of all the metabolites was directly obtained by the method of HPLC-DAD. The analytical HPLC system for the metabolites was composed of a Waters Delta 600 pump, a Waters 600 controller and a Waters 996 photodiode array detector (Waters, Milford, MA, U.S.A.) with a Millennium 32 workstation. The chromatographic separation was performed on a C 18 column (Inertsil ODS-2, 5 mm, 4.6ϫ250 mm) at a column temperature of 25°C, and mobile phase was MeOH-H 2 O (50 : 50), containing 0.1% phosphoric acid. . ESI-MS n in negative mode was shown in Fig. 3 . Metabolite M-2 (Scutellarein) Yellow amorphous powder, the l max of UV absorption is at 283, 337 nm, suggesting M-2 to be a flavonoid. The negative ESI-MS showed a quasi-
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molecular ion peak at m/z 285 [MϪH]
Ϫ which suggested M-2 to be the aglycone of scutellarin. In the 1 H-NMR, the signals of H-2Ј,6Ј (d 7.90, 2H, d, Jϭ8.6 Hz) and H-3Ј,5Ј (d 6.91, 2H, d, Jϭ8.6 Hz) indicated that ring B was substituted in position C-4Ј and the signal at d 12.78 (1H, s) was attributed to 5-OH characteristically. In the NOESY spectrum, the cross peak from H-3 (d 6.73, 1H, s) to H-2Ј,6Ј (d 7.90, 2H, d, Jϭ8.6 Hz) could be observed, and consequently, 6.73 (1H, s) was assigned to H-3, and 6.56 (1H, s) was ascribed to H-8 meanwhile. Compared with the published data, 13) the structure of M2 was identified as scutellarein. Compared the 13 C-NMR of M-3 with that of scutellarin, an additional signal at d 60.3 ppm appeared, the value of which above d 60.0 ppm indicated that the methoxyl group was diortho-substituted, 15) and meanwhile, downfield shift of C-5 by 5.5 ppm, downfield shift of C-6 by 1.9 ppm, downfield shift of C-7 by 7.4 ppm and downfield shift of C-9 by 1.1 ppm could be observed, suggesting the ring A of the agly- Table 1 .
Metabolite M-6 (Scutellarein-5-O-b b-D-glucuronide) Yellow amorphous powder, the l max of UV absorption is at 273, 333 nm, suggesting M-6 to be a flavonoid. Enzymatic hydrolysis of M-6 with b-glucuronidase gave the aglycone scutellarein identified by the ESI-MS and HPLC behavior. The negative ESI-MS 2 spectrum of M-6 was almost the same as that of M-5, suggesting M-6 to be an isomer of scutellarin as well. In the 1 H-NMR spectrum, the signal of 5-OH disappeared, and in the C-NMR spectrum, compared with that of scutellarein, upfield shift of C-7 by 5.0 ppm, downfield shift of C-6 by 2.9 ppm, downfield shift of C-8 by 4.7 ppm, and downfield shift of C-10 by 2.2 ppm could be observed, suggesting that the ring A of the flavonoid skeleton was sulfated, according to the shift rules of flavonoid after conjugated with sulfate, 17) M-8 was determined to be scutellarein-7-O-sulfate. The full assignment of proton signals are summarized in Table 1 . Table 1 . 
DISCUSSION
In recent years, considerable studies on the pharmacokinetics of breviscapine have been done, however, reports available on the metabolism of it in vivo after oral administration were limited to two published articles. 9, 18) The current study was our effort to discover the metabolic information of breviscapine in rats after oral administration, and ten metabolites were obtained, which might be useful for discussing the metabolism and disposition of breviscapine in vivo. Due to the possible instability of the metabolites during the experimental process, phosphoric acid was employed. Xing J. et al. have reported that acidification could stabilize flavonoids containing ortho-phenolic groups, and the structures like this are prone to be oxidized. 19) The structures of these metabolites were elucidated by MS, NMR spectroscopy including 1 H-NMR, 13 C-NMR, and NOESY, enzymatic hydrolysis and chemical methods. Among these metabolites, M-3 and M-4 were methylated ones, however, they might not be artifacts during the process of isolation and purification. According to our knowledge, the conclusion was supported by the article published previously, 9) in which they have discussed that the enzyme of methylation in the cell liquid of liver specifically metabolized o-hydroxyphenyl and they have discovered the two methylated products by the methods of HPLC-MS and HPLC-NMR.
Akao T. et al. have discussed that baicalin was transformed to its aglycone baicalein by intestinal bacteria and baicalein was absorbed intestinally and conjugated back to baicalin in the plasma after oral administration of baicalin to rats, 20) and Gafner S. et al. presumed that other flavone-7-Oglucuronides were absorbed in a similar way as baicalin. 15) Scutellarin, which have similar structure to baicalin, was detected in rat urine after oral administration in our study, and therefore we thought scutellarin might be obtained as a metabolite in the similar way. On the basis of the metabolites profile, the possible metabolic pathways of breviscapine in rats are shown in Figs 4, 5. Plantaginin, which had the same aglycone with scutellarin, was absorbed intestinally as the form of scutellarein, and due to its low content in breviscapine, we considered scutellarin had played a major role in the process of metabolism in vivo (Fig. 4) . Few data have reported dehydroxylation of flavonoids in vivo, and thus, we thought M-9 and M-10 were converted by apigenin-7-O-b-Dglucuronide (Fig. 5) . There existed P450 mediated hydroxylation metabolic reaction in vivo, however, it was demonstrated that glucuronidation of galangin was 30-fold more efficient than P450 mediated hydroxylation of galangin. 21) On the other hand, even though apigenin-7-O-b-D-glucuronide was hydroxylated to scutellarin in vivo, scutellarin derived from apigenin-7-O-b-D-glucuronide would be minor and could not be detected or obtained in the experimental condition due to the lower content of apigenin-7-O-b-D-glucuronide in breviscpine.
Comparisons of ESI-MS n data and retention time in HPLC with synthesized standards are usually used to identify the structures of metabolites in recent years. However, when the standards are difficult to synthesize, for instance, flavonoids with three vicinal phenolic groups like scutellarein, the aglycone of scutellarin, is hardly to be sulfated, due to the instability of these aglycones in the reaction conditions, 17) some metabolites' structures deduced only from LC/MS n data may not be correct, especially in the case of the existence of isomeric metabolites. In our study, M-5, M-6, and M-7, M-9 and M-10 were isomers of different linkage sites of the glucuronic acid, which have identical data in ESI-MS n . However, the linked positions of the glucuronic acid could hardly be determined only by mass spectra, as well as the assignments of the signals of H-3 and H-8 for the metabolites of scutellarin, and of H-3, H-6, and H-8 for apigenin-5-O-b-Dglucuronide, which could be determined by means of NMR technique such as NOESY. In these cases, preparation of metabolites and further identification based on NMR data must be done.
In summary, we have determined the definitive structures of ten metabolites derived from breviscapine by MS, NMR spectroscopy, enzymatic hydrolysis and chemical methods. Furthermore, M-8 and M-9 were new compounds. These results are important to understand the metabolic fate and disposition of breviscapine in rats, and would provide important information for studying its metabolism in humans.
